Amendment No 3 to Schedule 13D

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

 

 

Mirum Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

604749101

(CUSIP Number)

Peter Haahr

Novo Holdings A/S

Tuborg Havnevej 19

Hellerup, Denmark DK-2900

+45 3527 6592

Copy to:

B. Shayne Kennedy, Esq.

Latham & Watkins LLP

650 Town Center Drive, 20th Floor

Costa Mesa, CA 92626

Telephone: (714) 540-1235

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

August 19, 2021

(Date of Event which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is subject of this Schedule 13D, and is filing this statement because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.  ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

 

 

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No.: 604749101

 

  1.    

  Name of Reporting Person:

 

  Novo Holdings A/S

  2.  

  Check the Appropriate Box if a Member of Group (See Instructions):

  (a)  ☐        (b)  ☐

 

  3.  

  SEC Use Only:

 

  4.  

  Source of Funds:

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

 

  ☐

  6.  

  Citizenship or Place of Organization:

 

  Denmark

Number of

Shares

 Beneficially 

Owned By

Each

Reporting

Person With:

 

     7.     

  Sole Voting Power:

 

   2,445,147

     8.   

  Shared Voting Power:

 

  0

     9.   

  Sole Dispositive Power:

 

   2,445,147

   10.   

  Shared Dispositive Power:

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person:

 

   2,445,147

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares:

 

  ☐

13.  

  Percent of Class Represented By Amount In Row (11):

 

  8.0% (1)

 

(1)

Based upon 30,515,833 shares of the Issuer’s Common Stock outstanding as of July 30, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 8, 2021.

 

2


This amendment (“Amendment No. 3”) amends the Schedule 13D originally filed with the SEC on July 23, 2019, as amended by Amendment No. 1 filed on January 17, 2020 and Amendment No. 2 filed on December 18, 2020 (collectively, the “Schedule”), to report and reflect that Tiba Aynechi, a board member of the Issuer, resigned as a director effective August 19, 2021. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule. All capitalized terms contained herein but not otherwise defined shall have the meaning ascribed to such terms in the Schedule.

 

Item 2.

Identity and Background

Item 2 of the Schedule is amended and replaced in its entirety as follows:

 

  (a)

Novo Holdings A/S is a Danish corporation and an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the “Foundation”), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S and Novozymes A/S) and is responsible for managing the Foundation’s assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S. Tiba Aynechi, Ph.D. is employed as a partner at Novo Ventures (US), Inc. and was designated to the board of directors of the Issuer by Novo Holdings A/S in November 2018 and resigned as a board member effective August 19, 2021. Dr. Aynechi is not deemed to be a beneficial owner of the securities held by Novo Holdings A/S.

The name of each director and executive officer of both Novo Holdings A/S and the Foundation is set forth on Schedule I to this Schedule 13D.

 

  (b)

The business address of both Novo Holdings A/S and the Foundation is Tuborg Havnevej 19, 2900 Hellerup, Denmark.

The residence or business address of each director and executive officer of both Novo Holdings A/S and the Foundation is set forth on Schedule I to this Schedule 13D.

 

  (c)

Novo Holdings A/S, a holding company that is responsible for managing the Foundation’s assets, provides seed and venture capital to development stage companies and invests in well-established companies within the life science and biotechnology sector.

The Foundation is a Danish self-governing and profit-making foundation, whose objectives are to provide a stable basis for commercial and research activities undertaken by the group of Novo companies and to support scientific, humanitarian and social purposes through grants.

 

  (d)

Within the last five years, neither Novo Holdings A/S, the Foundation, nor any person named in Schedule I has been convicted in any criminal proceedings.

 

  (e)

Within the last five years, neither Novo Holdings A/S, the Foundation, nor any person named in Schedule I was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

Item 4.

Purpose of Transaction

Item 4 of the Schedule is amended and replaced in its entirety as follows:

The acquisitions of Issuer securities made by Novo Holdings A/S are for investment purposes. Novo Holdings A/S intends to review its investments in the Issuer on a continuing basis and any actions Novo Holdings A/S might undertake will be dependent upon its review of numerous factors from time to time, including, but not limited to: an ongoing evaluation of the Issuer’s business, financial condition, operations and prospects; price levels of the Issuer’s

 

3


securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments. Novo Holdings A/S may, at any time and from time to time, acquire additional securities of the Issuer, or retain or sell all or a portion of the securities of the Issuer then held, in the open market or in privately negotiated transactions. Tiba Aynechi is employed as a senior partner at Novo Ventures (US), Inc. and was designated to the board of directors of the Issuer by Novo Holdings A/S. Ms. Aynechi resigned as a director of the Issuer, effective August 19, 2021 and is not deemed to be a beneficial owner of the securities held by Novo Holdings A/S. Other than as described herein, Novo Holdings A/S currently does not have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)–(j) of Schedule 13D, although, depending on the factors discussed herein, Novo Holdings A/S may review or reconsider or change its purpose or formulate different plans, strategies, or proposals with respect thereto at any time.

 

Item 5.

Interest in Securities of the Issuer

Item 5 of the Schedule is amended and replaced in its entirety as follows:

(a) Novo Holdings A/S beneficially owns 2,445,147 shares of Common Stock (the “Novo Shares”) representing approximately 8.0% of the Issuer’s outstanding shares of Common Stock, based upon 30,515,833 shares of the Issuer’s Common Stock outstanding as of July 30, 2021, as reported in the Issuer’s Form 10-Q filed with the SEC on August 8, 2021.

(b) Novo Holdings A/S is a Danish corporation wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares.

(c) Except as described herein, Novo Holdings A/S has not effected any transactions in the Issuer’s Common Stock within the past 60 days and neither the Foundation nor any person listed on Schedule I has effected any transactions in the Issuer’s Common Stock within the past 60 days.

(d) Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares.

(e) Not applicable.

 

4


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated:    August 24, 2021     Novo Holdings A/S
   

/s/ Peter Haahr

    By:   Peter Haahr
    Its:   Chief Financial Officer


Schedule I

Information regarding each director and executive officer of both Novo Holdings A/S and the Novo Nordisk Foundation is set forth below.

 

Novo Holdings A/S

Name, Title

  

Address

  

Principal Occupation

  

Citizenship

Lars Rebien Sørensen,
Chairman of the Board
   Christianholms Tværvej 27,
2930 Klampenborg
Denmark
   Professional Board Director    Denmark
Steen Riisgaard,
Vice Chairman of the Board
   Hestetangsvej 155,
3520 Farum,
Denmark
   Professional Board Director    Denmark
Jean-Luc Butel,
Director
   235 Arcadia Road
unit # 10-3
289843 Singapore
   Global Healthcare Advisor,
President, K8 Global Pte Ltd.
   Singapore
Jeppe Christiansen,
Director
   c/o Kasper Fonager
Christiansen
Classensgade 59, 5. th.
2100 Kobenhavn Ø
Denmark
   Chief Executive Officer,
Fondsmaeglerselskabet Maj
Invest A/S
   Denmark
Francis Michael Cyprian Cuss,
Director
   111 Rippling Brook Way,
Bernardsville,
NJ 07924
USA
   Former Executive Vice President
and Chief Scientific Officer of
Bristol-Myers Squibb
   United Kingdom
Viviane Monges,
Director
   Chemin de Craivavers 32,
1012 Lausanne, Switzerland
   Professional Board Director    France
Henrik Poulsen,
Director
   Emiliekildevej 36
2930 Klampenborg
Denmark
   Professional Board Director and
Senior Advisor, A.P. Møller
Holding A/S,
   Denmark
Poul Carsten Stendevad,
Director
   3220 Idaho Ave NW
Washington, DC 20016
USA
   Co-Chief Investment Officer for
Sustainability, Bridgewater
Associates
   Denmark
Kasim Kutay,
Chief Executive Officer of Novo Holdings A/S
   Bredgade 65, 3.tv. 1260
Copenhagen K.
Denmark
   Chief Executive Officer of Novo
Holdings A/S
   United Kingdom
Peter Haahr,
Chief Financial Officer of Novo Holdings A/S
   Ordrup Have 21
2920 Charlottenlund
Denmark
   Chief Financial Officer of Novo
Holdings A/S
   Denmark

Novo Nordisk Foundation

Name, Title

  

Address

  

Principal Occupation

  

Citizenship

Lars Rebien Sørensen,
Chairman of the Board
   Christianholms Tværvej 27
2930 Klampenborg
Denmark
   Professional Board Director    Denmark


Novo Nordisk Foundation

Name, Title

  

Address

  

Principal Occupation

  

Citizenship

Marianne Philip,
Vice Chairman of the Board
   Annasvej 28
2900 Hellerup
Denmark
   Attorney    Denmark
Steen Riisgaard,
Director
   Hestetangsvej 155
3520 Farum
Denmark
   Professional Board Director    Denmark
Mads Krogsgaard Thomsen,
Chief Executive Officer
   Præstevejen 38
3230 Græsted
Denmark
   Chief Executive Officer, Novo
Nordisk Foundation
   Denmark
Anne Marie Kverneland,
Director
   Nybrovej 216
2800 Kgs. Lyngby
Denmark
   Laboratory technician, Novo
Nordisk A/S
   Denmark
Lars Bo Køppler,
Director
   Anemonevej 7
3550 Slangerup
Denmark
   Technician, Novozymes A/S    Denmark
Lars Henrik Fugger,
Director
   72 Staunton Road,
Headington
Great Britain
   Professor, John Radcliffe Hospital,
University of Oxford, Oxford,
Great Britain
   Denmark
Lars Henrik Munch,
Director
   Galionsvej 46
1437 Copenhagen K
Denmark
   Professional Board Director    Denmark
Mads Boritz Grøn,
Director
   Horsevænget 4
3400 Hillerød
Denmark
   Senior Lead Auditor    Denmark
Liselotte Højgaard,
Director
  

Grønningen 21

1270 Copenhagen K
Denmark

   Professor    Denmark